INNOVENT BIO (01801) announced that on March 30, 2026, the company granted 1.94 million share options to 66 grantees, including directors, and issued 10.24 million restricted shares to 1,308 grantees under the terms of the 2024 Share Scheme, subject to acceptance by the recipients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments